Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor

Circulation. 2011 Feb 1;123(4):451-6. doi: 10.1161/CIRCULATIONAHA.110.985325. Epub 2011 Jan 17.

Authors

Michael A Gaglia Jr¹, Ron Waksman

Affiliation

¹ Division of Cardiology, Washington Hospital Center, Washington, DC, USA.

PMID: 21242480
DOI: 10.1161/CIRCULATIONAHA.110.985325

No abstract available

MeSH terms

Acute Coronary Syndrome / drug therapy*
Adenosine / adverse effects
Adenosine / analogs & derivatives*
Adenosine / pharmacokinetics
Adenosine / therapeutic use
Advisory Committees / legislation & jurisprudence
Aspirin / adverse effects
Aspirin / therapeutic use
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Clopidogrel
Drug Approval*
Humans
Multicenter Studies as Topic
Platelet Aggregation Inhibitors / pharmacokinetics
Platelet Aggregation Inhibitors / therapeutic use*
Purinergic P2Y Receptor Antagonists / adverse effects
Purinergic P2Y Receptor Antagonists / pharmacokinetics
Purinergic P2Y Receptor Antagonists / therapeutic use*
Randomized Controlled Trials as Topic
Thrombosis / drug therapy
Thrombosis / mortality
Thrombosis / prevention & control
Ticagrelor
Ticlopidine / adverse effects
Ticlopidine / analogs & derivatives
Ticlopidine / therapeutic use
United States

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Clopidogrel
Ticagrelor
Adenosine
Ticlopidine
Aspirin